Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS), Elevance Health (ELV) and Universal Health (UHS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corvus Pharmaceuticals (CRVS – Research Report), Elevance Health (ELV – Research Report) and Universal Health (UHS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Corvus Pharmaceuticals (CRVS)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corvus Pharmaceuticals today and set a price target of $30.00. The company’s shares closed last Wednesday at $20.54.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Corvus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $31.80, representing a 44.0% upside. In a report issued on January 20, TipRanks – Google also upgraded the stock to Buy with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Elevance Health (ELV)
Bank of America Securities analyst Kevin Fischbeck reiterated a Hold rating on Elevance Health today and set a price target of $385.00. The company’s shares closed last Wednesday at $341.85.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
Elevance Health has an analyst consensus of Strong Buy, with a price target consensus of $396.36, a 25.6% upside from current levels. In a report released yesterday, TipRanks – OpenAI also downgraded the stock to Hold with a $349.00 price target.
Universal Health (UHS)
Wells Fargo analyst Stephen Baxter maintained a Hold rating on Universal Health yesterday and set a price target of $235.00. The company’s shares closed last Wednesday at $203.02.
According to TipRanks.com, Baxter is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $253.00 average price target, a 25.5% upside from current levels. In a report issued on January 22, RBC Capital also maintained a Hold rating on the stock with a $231.00 price target.
